Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service skin substitutes & wound grafts cases in Arkansas: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (246 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 9 | 1,638 | 29% |
| 2020 | 10 | 1,814 | 32% |
| 2021 | 7 |
Application of cellular and tissue-based products to wounds; the loudest category in Open Payments. Professional codes (what the surgeon bills): CPT 15271, 15273, 15275, 15277.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 81% of the cases CMS names in Arkansas; 10 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Debridement & negative-pressure wound therapy | 132 | 29,280−1.7%/yr | −1.7%/yr | 74.30.6× | 32% | 33,700 in 2030+2.4%/yr |
| Bone graft & orthobiologics |
Skin substitutes & wound grafts in every state, and its device makers · Every procedure market in Arkansas · Every state · Compare with Florida
| 2024 |
| 4,095 |
| 49% |
| 2025 est. | ≈ 4,430 | – |
| 2026 est. | ≈ 4,850 | – |
| 2,059 |
| 37% |
| 2022 | 14 | 2,368 | 40% |
| 2023 | 10 | 2,785 | 46% |
| 2024 | 17 | 4,095 | 49% |
| 2025 from claims | – | 4,431 4,067–4,688 | 50% |
| 2026 forecast | – | 4,848 4,265–5,594 | 51% |
| 2027 forecast | – | 5,303 4,534–6,320 | 51% |
| 2028 forecast | – | 5,801 4,840–7,103 | 52% |
| 2029 forecast | – | 6,344 5,181–7,956 | 53% |
| 2030 forecast | – | 6,937 5,557–8,889 | 53% |
In 2025, 1% inpatient hospital, 26% hospital outpatient, 73% office. The share outside the hospital has moved +35 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Office |
|---|---|---|---|
| 2026 · ~4,800 | ~35 | ~1,200 | ~3,600 |
| 2027 · ~5,300 | ~40 | ~1,200 | ~4,000 |
| 2028 · ~5,800 | ~45 | ~1,300 | ~4,400 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: hospital outpatient about 23% (26% in 2025), office about 76% (73% in 2025).
| 48,756+22%/yr |
| +22%/yr |
| 13.2 |
| 77% |
| 79,300 in 2030+8.4%/yr |
| Georgia | 65 | 14,399+9.3%/yr | +9.3%/yr | 9.7 | 74% | 20,000 in 2030+5.6%/yr |
| Oklahoma | 48 | 11,719+21%/yr | +21%/yr | 16.6 | 72% | 19,200 in 2030+8.6%/yr |
| Tennessee | 38 | 9,735+16%/yr | +16%/yr | 8.3 | 69% | 15,600 in 2030+8.1%/yr |
| Virginia | 47 | 9,709+14%/yr | +14%/yr | 6.5 | 70% | 21,900 in 2030+14%/yr |
| South Carolina | 44 | 8,777+14%/yr | +14%/yr | 8.4 | 72% | 16,300 in 2030+11%/yr |
| Mississippi | 39 | 8,487+28%/yr | +28%/yr | 15.3 | 68% | 14,900 in 2030+9.8%/yr |
| Alabama | 31 | 7,567+19%/yr | +19%/yr | 9.4 | 82% | 11,800 in 2030+7.7%/yr |
| North Carolina | 35 | 7,475+4.4%/yr | +4.4%/yr | 4.4 | 66% | 10,800 in 2030+6.4%/yr |
| Kentucky | 24 | 7,085+18%/yr | +18%/yr | 9.2 | 65% | 11,400 in 2030+8.3%/yr |
| Louisiana | 33 | 6,694+10%/yr | +10%/yr | 9.4 | 82% | 12,700 in 2030+11%/yr |
| Maryland | 25 | 5,850+12%/yr | +12%/yr | 5.3 | 70% | 12,200 in 2030+13%/yr |
| West Virginia | 12 | 3,280+21%/yr | +21%/yr | 9.3 | 82% | 4,240 in 2030+4.4%/yr |
| Delaware | 5 | 1,763+16%/yr | +16%/yr | 7.8 | 92% | 3,650 in 2030+13%/yr |
| District of Columbia | 4 | 1,007+12%/yr | +12%/yr | 11.6 | 83% | 2,200 in 2030+14%/yr |
| 8 |
| 484−8.7%/yr |
| −8.7%/yr |
| 1.21.8× |
| 2% |
| 370 in 2030−4.3%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Biotissue Holdings leads with 41% of company spending on these surgeons in 2025, +37 pts on 2024.
In 2025, 26 companies reported engagement with Arkansas’s surgeons worth $51K in consulting, speaking, meals and travel tied to these products, about $2,991 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 37 clearances and approvals in the category, 13 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.